Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1994; 71(03): 375-394
DOI: 10.1055/s-0038-1642446
DOI: 10.1055/s-0038-1642446
Scientific and Standardization Committee Communications
Nomenclature of Quantities and Units in Thrombosis and Haemostasis (Recommendation 1993)
A Collaborative Project of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH/SSC) and the Commission/Committee on Quantities and Units (in Clinical Chemistry) of the International Union of Pure and Applied Chemistry-International Federation of Clinical Chemistry (IUPAC-IFCC/CQU(CC))Authors
-
M Blombäck
Department of Clinical Chemistry and Blood Coagulation, Karolinska Hospital, Stockholm, Sweden)
Chairman of the SSC Nomenclature Project and Past-Chairman of the SSC:
(
Authors
-
U Abildgaard
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
A M H P van den Besselaar
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
K J Clementson
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
B Dahlbäck
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
T Exner
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
C W Francis
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
P Gaffney
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
H Grainick
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
L W Hoyer
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
G J Johnson
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
C Kasper
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
D Lane
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
H R Lijnen
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
J M Lusher
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
P M Mannucci
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
L Poller
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
S I Rapaport
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
H Salto
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
K Stocker
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom -
D Thomas
1 The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom)
Chairs and co-chairs of the SSC's scientific subcommittees:
(
Authors
-
T W Barrowcliffe
2 NIBSC, Hertfordshire, United Kingdom; and Cardiovascular Res. Institute, Maastricht, The Netherlands; and Dept, Clin, Biochem., Univ. Hospital of Copenhagen, Denmark; and George Washington University School of Medicine, Washington, DC, USA; and Hopital de Bicetre, France; and International Headquarters of ISTH, UNC Med. School, Chapel Hill, North Carolina, USA; and Dept. Clin. Chem,, Frederiksberg Hospital, Copenhagen, Denmark; and Dept, of Clin, Biochem., Univ. Hospital of Copenhagen, Denmark -
C S Thorsen Hemker
2 NIBSC, Hertfordshire, United Kingdom; and Cardiovascular Res. Institute, Maastricht, The Netherlands; and Dept, Clin, Biochem., Univ. Hospital of Copenhagen, Denmark; and George Washington University School of Medicine, Washington, DC, USA; and Hopital de Bicetre, France; and International Headquarters of ISTH, UNC Med. School, Chapel Hill, North Carolina, USA; and Dept. Clin. Chem,, Frederiksberg Hospital, Copenhagen, Denmark; and Dept, of Clin, Biochem., Univ. Hospital of Copenhagen, Denmark -
D Aronson
2 NIBSC, Hertfordshire, United Kingdom; and Cardiovascular Res. Institute, Maastricht, The Netherlands; and Dept, Clin, Biochem., Univ. Hospital of Copenhagen, Denmark; and George Washington University School of Medicine, Washington, DC, USA; and Hopital de Bicetre, France; and International Headquarters of ISTH, UNC Med. School, Chapel Hill, North Carolina, USA; and Dept. Clin. Chem,, Frederiksberg Hospital, Copenhagen, Denmark; and Dept, of Clin, Biochem., Univ. Hospital of Copenhagen, Denmark -
K G Mann
2 NIBSC, Hertfordshire, United Kingdom; and Cardiovascular Res. Institute, Maastricht, The Netherlands; and Dept, Clin, Biochem., Univ. Hospital of Copenhagen, Denmark; and George Washington University School of Medicine, Washington, DC, USA; and Hopital de Bicetre, France; and International Headquarters of ISTH, UNC Med. School, Chapel Hill, North Carolina, USA; and Dept. Clin. Chem,, Frederiksberg Hospital, Copenhagen, Denmark; and Dept, of Clin, Biochem., Univ. Hospital of Copenhagen, Denmark -
Dominique Meyer
2 NIBSC, Hertfordshire, United Kingdom; and Cardiovascular Res. Institute, Maastricht, The Netherlands; and Dept, Clin, Biochem., Univ. Hospital of Copenhagen, Denmark; and George Washington University School of Medicine, Washington, DC, USA; and Hopital de Bicetre, France; and International Headquarters of ISTH, UNC Med. School, Chapel Hill, North Carolina, USA; and Dept. Clin. Chem,, Frederiksberg Hospital, Copenhagen, Denmark; and Dept, of Clin, Biochem., Univ. Hospital of Copenhagen, Denmark -
H R Roberts
2 NIBSC, Hertfordshire, United Kingdom; and Cardiovascular Res. Institute, Maastricht, The Netherlands; and Dept, Clin, Biochem., Univ. Hospital of Copenhagen, Denmark; and George Washington University School of Medicine, Washington, DC, USA; and Hopital de Bicetre, France; and International Headquarters of ISTH, UNC Med. School, Chapel Hill, North Carolina, USA; and Dept. Clin. Chem,, Frederiksberg Hospital, Copenhagen, Denmark; and Dept, of Clin, Biochem., Univ. Hospital of Copenhagen, Denmark)
Ad hoc consultants:
(
Authors
-
R Dybkær
-
K Jørgensen
-
H Olesen
)
IUPAC Commission on Quantities and Units in Clinical Chemistry and IFCC Committee
on Quantities and Units:
(
Further Information
Publication History
Publication Date:
21 August 2018 (online)
-
References
- 1 Dybkaer R, Jprgensen K. Measurement, value and scale. Scand J Clin Lab Invest 49 Suppl 194: 69-76 1989;
- 2 International Union of Pure and Applied Chemistry and International Federation of Clinical Chemistry. Commission/Committee on Quantities and Units (in Clinical Chemistry). A proposal for a IUPAC-IFCC Recommendation. Quantities and Units in Clinical Laboratory Sciences. Mail ballot 1994-01.
- 3 Twelfth International Congress of Anatomists in London, 1985. Nomina Anatomica, 6th ed. Prepared by the International Anatomical Nomenclature Committee. London: Churchill Livingstone, 1989.
- 4 WHO (World Health Organization). The SI for the Health Professions. Prepared at the request of the Thirtieth World Health Assembly. Geneva: WHO, 1977.